Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.

IDH mutations may define a unique subset of melanoma patients who are eligible for IDH1 targeted therapies or combined therapies, such as MEK inhibitors when there is co-existing NRAS mutations, or immunotherapy.